Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

Yasuyoshi Kawato, Masashi Aonuma, Yasuhide Hirota et al. · PubMed · 1991 · 874 citations

Medicine, Oncology, Pharmacology +13

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Yukio Ando, Hideo Saka, Maki Ando et al. · PubMed · 2000 · 788 citations

Medicine, Genetics, Pharmacology +15

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Ron H.J. Mathijssen, R J van Alphen, Jaco J. Verweij et al. · PubMed · 2001 · 752 citations · Full text

Medicine, Oncology, Pharmacology +17

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

Lalitha Iyer, Christopher D. King, P. F. Whitington et al. · Journal of Clinical Investigation · 1998 · 680 citations · Full text

Medicine, Oncology, Pharmacology +17

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics

Yohei Nishizato · Clinical Pharmacology & Therapeutics · 2003 · 511 citations

Pharmacy, Genetics, Pharmacology +16